ESTEVE PHARMACEUTICALS
LIVE

Serial Number

99044353

Owner

ESTEVE PHARMACEUTICALS, S.A.

Attorney

G PATRICK SAGE II

Filing Date

Feb 17, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ESTEVE PHARMACEUTICALS Trademark

Serial Number: 99044353 • Registration: 8099251

ESTEVE PHARMACEUTICALS is a trademark filed by ESTEVE PHARMACEUTICALS, S.A. on February 17, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ESTEVE PHARMACEUTICALS, S.A. (28 trademarks)

TORRE ESTEVE,

Entity Type: 99

Trademark Details

Filing Date

February 17, 2025

Registration Date

January 13, 2026

Published for Opposition

November 25, 2025

Goods & Services

Pharmaceutical preparations for the treatment of metabolic disorders, namely, for treating diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations for the treatment of the endocrine system, namely, for treating growth and thyroid disorders; Pharmaceutical preparations for the treatment of the musculoskeletal system, namely, for treating connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, and cartilage injuries; Pharmaceutical preparations for the treatment of genitourinary diseases, namely, for treating urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of neurological diseases, namely, for use in treating Alzheimer's disease, Huntington's disease, cerebral palsy, brain injuries, spinal cord injuries, and seizure disorders; Pharmaceutical preparations for the treatment of hormonal disorders, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, and thyroid hormone preparations; Pharmaceutical preparations for the treatment of psychiatric diseases, namely, for treating mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, and immune system related diseases and disorders; Pharmaceutical preparations for use in dermatology, namely, for use in treating dermatitis, eczema, psoriasis, skin pigmentation diseases, and dermatological sexually transmitted diseases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 13, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 13, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 27, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 27, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 27, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 27, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 27, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 26, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 23, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 17, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 17, 2025 NWOS
NEW APPLICATION ENTERED
Feb 17, 2025 NWAP